Because of its hypermethylation, low Pitx2 expression had been reported in patients with breast cancer [6, 7], prostate cancer [8, 9], and colon cancer [10], which was considered to be a potential predictor of poor clinical outcomes. This evidence concerns the gene PITX2 and prostate carcinoma.